Evaluation of Biomarkers for Predicting Macronutrient Intake

Launched by TEXAS A&M UNIVERSITY · Aug 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how the food we eat affects certain small markers found in our blood and body fluids. Researchers want to find out if they can use wearable devices to accurately measure how different nutrients, like carbohydrates and proteins, are available to our bodies in real time. This information could help improve our understanding of nutrition and health.

To participate, you need to be between 50 and 75 years old, have a body mass index (BMI) between 25 and 35, and be able to move around independently. The study involves one screening visit lasting about 2 hours, where your height, weight, and body composition will be measured, and then up to 4 study days, each lasting about 14 hours. On these days, you will need to arrive without eating beforehand. Overall, this study aims to gather important information about how our bodies process food, which could lead to better health outcomes in the future.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Ability to walk, sit down and stand up independently
• • Age 50-75 years old
• • Ability to lie in supine or slightly elevated position for approximately 13 hours
• • BMI between 25 and 35
• • Willingness and ability to comply with the protocol
• • Exclusion Criteria
• • Established diagnosis of malignancy
• • Established diagnosis of Insulin or non-Insulin Dependent Diabetes Mellitus
• • History of untreated metabolic diseases including hepatic or renal disorder
• • Currently on anticoagulants (i.e., warfarin, factor X inhibitors or direct thrombin inhibitors)
• • History of deep vein thrombosis, pulmonary embolisms, or known clotting disorders
• • Presence of acute illness or metabolically unstable chronic illness
• • Recent myocardial infarction (less than 1 year)
• • Known allergy or intolerance to any of the meal components
• • Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
• • Failure to give informed consent or Investigator\'s uncertainty about the willingness or ability of the participant to comply with the protocol requirements